Long-Term Follow-Up Study for KYV-101 Participants
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This long-term follow-up study checks on the health and safety of people who have already received the experimental cell therapy KYV-101 in a previous clinical trial. It is a way for them to be monitored over time without any additional treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already received at least one dose of the study drug KYV-101 in a previous study.
- You must agree to join this long-term follow-up study and sign a consent form.
- There are no other specific medical requirements or restrictions for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
This study tests a new immune therapy called CAR T-cells (KYV-101) for people with active, tough-to-treat dermatomyositis. It aims to see if the treatment is safe and can reduce muscle weakness and skin rash.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial is testing a type of immunotherapy called CAR-T cells (made from your own immune cells) to see if it can help slow or stop progressive multiple sclerosis. It is a very early safety study, so only people with progressive MS who meet strict health criteria can join.
This study monitors participants who have received a SynKIR CAR T cell treatment in a past Verismo Therapeutics trial. It aims to track long-term health and safety outcomes over time.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
Hear when a new Refractory Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.